RxDoctor Payments Data

Donald Oh, MD

Psychiatry · Toms River, NJNPI 1548321649

Payments from drug & device makers

$252in general payments, 2019–2025

Across 11 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$131
  • Takeda Pharmaceuticals U.S.A., Inc.$43
  • E.r. Squibb & Sons, L.L.C.$27
  • AbbVie$25
  • Bausch Health US, LLC$13
  • Supernus Pharmaceuticals, Inc.$13

What the payments were for

  • Food & beverage$22589%
  • Education$2711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$252 in reported general payments places this provider in the 50th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$249,794
Medicare patients
152
Services billed
2,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate60$145,384
RexultiBrexpiprazole47$53,252
VraylarCariprazine Hcl18$35,430
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl268$22,048
Lurasidone Hcl68$17,915
TrintellixVortioxetine Hydrobromide15$10,503
XanaxAlprazolam11$6,448
Desvenlafaxine Succinate ErDesvenlafaxine Succinate157$5,850
Quetiapine Fumarate436$5,578
Clonazepam695$4,884
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine121$4,771
VyvanseLisdexamfetamine Dimesylate13$4,706
Alprazolam652$4,367
Aripiprazole145$3,126
Olanzapine144$2,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$131$53,25247 claims
AbbVieVraylar$25$35,43018 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$43$15,20828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →